New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis

• Published in: Current rheumatology reports 2020-07, Vol.22 (7), p.25-25, Article 25
• Main Authors: Dufrost, Virginie, Darnige, Luc, Reshetnyak, Tatiana, Vorobyeva, Maria, Jiang, Xin, Yan, Xin-xin, Gerotziafas, Grigorios, Jing, Zhi-Cheng, Elalamy, Ismaël, Wahl, Denis, Zuily, Stéphane
• Format: Article
• Language: English
• Subjects: Antiphospholipid Syndrome (S Zuily; Life Sciences; Medicine; Medicine & Public Health; Rheumatology; Section Editor; Topical Collection on Antiphospholipid Syndrome
• ISSN: 1523-3774; 1534-6307
• DOI: 10.1007/s11926-020-00901-y

Purpose of Review The efficacy of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS) is discussed. Results from randomized controlled trials are available. It has been stated that a history of arterial thrombosis and triple positivity was associated with a higher risk of thrombosis in APS patients treated with DOACs. However, their efficacy in non-high-risk APS patients with isolated venous manifestations is unsolved. Therefore, we performed a sub-group analysis of a previously published meta-analysis after the exclusion of patients with triple positivity and those with history of arterial or small vessel thrombosis. Recent Findings We identified 290 APS patients with previous isolated venous event treated with DOACs; among them, 25 (8.6%) patients experienced a recurrent thrombosis in comparison to 16% in the original cohort. Summary We found that the rate of recurrent thrombosis is lower in APS patients with isolated venous manifestations than in overall APS patients including high-risk patients. Research about DOAC use in non-high-risk APS patients needs to be continued.